Cardiac Monitors in New York

Avery Biomedical Devices manufactures the Avery Diaphragm Pacing System, a fully implantable phrenic nerve stimulator designed to provide vent-free breathing for patients with chronic respiratory muscle paralysis or central alveolar hypoventilation. The system consists of surgically implanted receivers and electrodes that respond to radio frequency signals from an external transmitter and antennas, stimulating the diaphragm to contract and enable natural breathing. Indications include high spinal cord injury, congenital and acquired central sleep apnea, and diaphragm paralysis from various etiologies. The device features dual redundant design ensuring no single-point failure, platinum electrodes, and dual alarm systems. The company holds FDA PMA approval for adult and pediatric use and CE marking privileges for EU markets. Key benefits include improved quality of life with greater mobility, reduced infection and hospitalization risk, lower annual operating costs (estimated $20,000+ savings versus mechanical ventilation), minimal ongoing wound care, and compatibility with water therapy. Technical support is provided at no additional cost. Reimbursement is available through Medicare and most private and government insurance plans. Avery has maintained an unsurpassed safety and reliability record spanning over 50 years of clinical use. The system is indicated for patients whose remaining phrenic nerve, lung, and diaphragm function is sufficient to accommodate electrical stimulation.

Global Instrumentation, LLC provides customized cardiac diagnostic and monitoring solutions for clinical researchers, contract research organizations, core labs, remote cardiac monitoring service providers, and medical technology OEMs. The company specializes in precision ECG data collection, ambulatory blood pressure monitoring (ABPM), and enterprise-level data management platforms for cardiac safety assessment in clinical trials (Phase 1–5). Product portfolio includes the M5 Wearable ECG Recorder (ultra-compact, 21-day ambulatory recording capability), M12R Holter & ECG Recorder (simultaneous 12-lead real-time and long-term monitoring), M12R Lite (portable 12-lead acquisition with Bluetooth connectivity), M12A Enterprise Software Platform (scalable cloud-based data acquisition, management, and analysis system for ECG and ABP data), and Oscar 2 Ambulatory Blood Pressure Monitor (24-hour ABPM standard). The M12A platform integrates multiple devices and enables centralized data collection, analytics, reporting, and secure storage across geographically distributed trials. Solutions are used in thousands of clinical trials globally. The company emphasizes patient-friendly device design, flexible cloud deployment, precision analytics, and streamlined regulatory submission workflows. Services include custom software development and OEM partnerships for cardiac sensors and monitoring systems.

SoftLink International is a healthcare IT company headquartered in India, founded in 1997, specializing in software solutions for hospital automation, clinical informatics, patient workflow management, and analytics. The company serves over 450 healthcare institutions across 15 countries, with significant deployments in the USA, Middle East, India, and Far East. Core product offerings include PANACEA (Hospital Information Management System/HIMS), a comprehensive EHR/EMR platform supporting full hospital digitization and paperless operations; Cardiology Solutions (CVIS—Cardiovascular Information System) providing multimodality viewing, cath lab inventory management, and research tools; Radiology Solutions delivering end-to-end PACS (Picture Archiving and Communication Systems) from single clinics to enterprise deployments; and TeleHealth Solutions functioning as standalone or integrated remote consultation platforms. The company maintains compliance certifications including FDA, HIPAA, ISO 9001, ISO 27001, DICOM, HL7, ICD-10, and IHE standards. SoftLink provides custom engineering, system integration, and data migration services. Known strengths include deep EHR/EMR integration experience (compatibility with EPIC, Cerner, and proprietary systems), support for non-DICOM modalities, and agile product innovation. The firm operates on a turnkey model, reducing dependency on third-party vendors. Clientele includes major hospital chains (Apollo, Fortis, Max Healthcare, Mount Sinai), government medical institutions (JIPMER), and specialty centers across multiple disciplines.

Retia Medical Systems develops cardiovascular surveillance software and hemodynamic monitoring solutions for intensive care, operating rooms, and perioperative environments. The company's core offering is the Argos® Cardiac Output Monitor, a bedside hemodynamic monitoring device that derives reliable cardiac output and cardiovascular insight from routine physiologic signals without requiring proprietary disposable sensors. The Argos Infinity™ platform extends this capability enterprise-wide, deploying the company's Multi-Beat Analysis (MBA) algorithm across hospital systems and tele-ICU environments to enable centralized cardiovascular surveillance and analytics. Retia's technology is designed to detect hemodynamic instability earlier than traditional vital sign monitoring, particularly in complex scenarios including arrhythmia, cardiogenic shock, low-flow states, and unstable blood pressure. The software integrates with existing monitoring and tele-ICU platforms, transforming real-time physiologic data into actionable clinical intelligence. Deployed in 75+ hospitals including major academic medical centers (Johns Hopkins, Duke Health, Cleveland Clinic, University Hospitals Cleveland, Texas Health Resources, UMC Health System, Rabin Medical Center), the solution has been validated in 14 peer-reviewed clinical studies. Retia received FDA 510(k) clearance for Argos Infinity. The company targets high-risk populations including cardiac and vascular surgery, sepsis, transplant, trauma, burns, and neurocritical care. Primary value propositions include elimination of disposable sensor costs, intuitive bedside workflow design, and system-wide scalability without infrastructure burden.

Nasiff Associates, Inc. is a US-based medical technology manufacturer specializing in PC-based ECG (electrocardiogram) diagnostic systems. Founded in 1989 and veteran-owned, the company designs and manufactures CardioCard ECG systems for use in hospitals, clinical offices, telehealth platforms, and home-based medical services. All devices are manufactured domestically in the United States and feature integrated software designed to connect with major EMR systems via the proprietary Cardio Universal EMR Interface. The product line includes resting ECG machines, stress testing systems, and Holter monitoring devices, all running on a unified software platform that allows clinicians to manage multiple diagnostic ECG modalities through a single interface. Nasiff markets its solutions as providing accurate signal acquisition, reliable interpretation, and meaningful clinical decision-making support for cardiovascular disease screening and management. The company emphasizes all-American sales and technical support, with a dedicated US-based customer support team providing live technical assistance. FDA clearance is obtained for its devices, and the company holds veteran-owned small business status.

VasoMedical, Inc. is a cardiovascular technology company with nearly 40 years of experience in cardiac diagnostics and therapy. The company specializes in two primary product areas: Enhanced External Counterpulsation (EECP®) therapy systems and next-generation cardiac monitoring platforms. Their Lumenair™ EECP® system is deployed in over 600 clinics across 40+ countries and is used for non-invasive therapy to improve coronary circulation, helping patients with angina and heart failure improve exercise tolerance and quality of life. In cardiac monitoring, VasoMedical offers the ARCS cloud-native platform, an FDA-cleared system for Holter, Extended Holter, Event, and Multi-Channel Telemetry (MCT) monitoring. ARCS features artifact-reduction algorithms, unified workflow management, and high-volume scanning capabilities designed to reduce manual rework and accelerate turnaround times. The company has analyzed over 1 billion heartbeats and delivered 12+ million hours of cardiac monitoring data. VasoMedical also provides the Advanced Cardiac Therapy (ACT) Program, a comprehensive utilization and operations model to help health systems optimize EECP program performance across cardiology, rehabilitation, and administrative workflows. The company serves hospitals, cardiology practices, rehabilitation clinics, and health systems ranging from private practices to major healthcare networks. Products are supported by FDA clearance for monitoring algorithms and established reimbursement pathways. VasoMedical combines hardware, software, and operational consulting to address both clinical and workflow challenges in cardiac care.

Axon Therapies, Inc. (registered trade name of Axon Vascular, Inc.) is a clinical-stage medtech company developing the Satera Ablation System for treatment of heart failure with preserved ejection fraction (HFpEF). The company's proprietary SAVM (Splanchnic Ablation for Volume Management) procedure uses an ablation catheter to target the greater splanchnic nerve via percutaneous venous access, aiming to reduce sympathetic nervous system activity and normalize volume balance in heart failure patients. The minimally invasive, implant-free outpatient procedure typically takes under one hour. Axon's lead investigational device is the Axon Ablation Catheter, designed to deliver targeted ablation therapy to block sympathetic nerve signals and reverse cardiac congestion. The company is currently conducting the Rebalance-HF clinical trial (NCT04592445), which demonstrated 12-month results showing reduced pulmonary capillary wedge pressure (PCWP) by 18 mmHg versus sham, improved quality of life (KCCQ +17), and increased six-minute walk distance (+49 meters). The device is investigational and not yet approved for clinical use in any geography. Axon is backed by institutional investors including Deerfield Management, Action Potential Venture Capital (GSK's bioelectronic medicines fund), and has assembled an experienced leadership team with deep medtech commercialization expertise and clinical advisory board comprising leading cardiologists from Mayo Clinic, Duke University, Northwestern University, Mount Sinai, and the Medical University of South Carolina. The company maintains offices in New York and Altrincham, United Kingdom.

AngioDynamics, Inc. is a medical device manufacturer specializing in innovative interventional oncology and peripheral vascular disease treatment solutions. The company develops and markets advanced percutaneous medical devices and systems designed to improve patient outcomes in two primary clinical areas: cardiovascular disease management and cancer treatment. Key product platforms include the Auryon System, a peripheral atherectomy device for treating arterial lesions and peripheral artery disease; the AlphaVac System, designed for efficient clot removal from large vessels; and the NanoKnife System, a precision ablation platform for oncologic and cardiac applications. These systems leverage advanced technologies including irreversible electroporation, mechanical thrombectomy, and minimally invasive atherectomy. The company is committed to clinical evidence generation, with active research and clinical studies demonstrating safety and efficacy. AngioDynamics serves interventional radiologists, interventional cardiologists, and surgical oncologists across hospital and outpatient settings. The organization emphasizes partnerships in care and maintaining a talented workforce dedicated to advancing medical innovation. Based in Glens Falls, New York, AngioDynamics operates as a publicly traded medical device innovator focused on expanding treatment options and developing care pathways for cardiovascular and oncologic patient populations.

Netech Corporation is a US-based manufacturer of biomedical test equipment and patient simulators for medical device validation and clinical training. Founded over 33 years ago, the company specializes in portable, easy-to-use testing instruments designed for hospital clinical engineering, biomedical maintenance, device manufacturers, and training institutions. Product categories include patient simulators (ECG, EEG, SpO2, pacemaker), defibrillator analyzers, infusion pump analyzers, electrical safety analyzers, pressure meters, and gas flow meters. The MiniSim product line offers compact, modular waveform generators for testing cardiac monitors, EEG recorders, and multi-parameter patient monitoring systems. The EXPMT 2000 External Pacemaker Analyzer is designed for atrial, ventricular, and transcutaneous pacemaker testing. All products are manufactured in the USA. Netech serves clinical engineering departments, biomedical equipment manufacturers, healthcare training centers, and medical device testing laboratories. The company emphasizes quality, reliability, and value in regulatory and performance testing workflows. Equipment is used for device validation, preventive maintenance, troubleshooting, and competency-based training. Netech's offerings support compliance with medical device testing standards and clinical engineering protocols.

Premier Heart, LLC manufactures and markets the Multifunction Cardiogram (MCG), a computer-based digital signal processing and analysis platform for non-invasive cardiac diagnostics. The MCG requires only a brief 10-minute resting electrocardiogram (ECG) that can be performed in-office, emergency departments, urgent care facilities, hospital bedsides, mobile clinics, or patient homes. The system delivers rapid results—typically within 30 minutes of test order—providing physicians with advanced diagnostic capabilities beyond conventional imaging and stress testing. Clinical trials have demonstrated high sensitivity (90%) and specificity (85%) in detecting clinically relevant ischemic heart conditions, performance metrics described as unrivaled among non-invasive cardiac diagnostic tools. The MCG analysis process takes approximately 15 minutes per patient, combining ECG acquisition with digital analysis to support rapid clinical decision-making in cardiology and emergency medicine settings. The platform is positioned as a cost-effective alternative to traditional stress tests and imaging studies for initial cardiac risk stratification and ischemic detection.

Aidoc is a healthcare AI software company founded in 2016, providing clinical decision support solutions built on its proprietary aiOS™ platform. The company delivers AI-powered medical imaging analysis and clinical intelligence tools across radiology, cardiology, neurovascular, and vascular care specialties. Aidoc's algorithms automatically analyze medical imaging (primarily CT scans) to detect acute pathologies, identify incidental findings, and prioritize critical cases for rapid clinical intervention. The platform integrates with hospital workflows to improve notification time-to-treatment, enhance care team coordination, and optimize patient management across departments. Serving over 1,600 medical centers globally and analyzing imaging for approximately 45 million patients annually, Aidoc enables healthcare systems to cover approximately 75% of their patient populations with AI-assisted clinical decision support. Key clinical applications include stroke detection and door-to-puncture time reduction, pulmonary embolism prioritization, cardiac disease measurement, and vascular pathology management.

Aerotel Medical Systems is a global provider of remote patient monitoring and telemedicine solutions specializing in 12-lead ECG cardiac monitoring. The company manufactures portable, user-friendly ECG devices combined with cloud-based call center software and transtelephonic transmission capabilities for real-time patient data transfer via Internet, cellular, or telephone networks. Aerotel's product portfolio includes the HeartView 12L (professional handheld 12-lead ECG), HeartView P12/8i (Bluetooth-enabled personal ECG recorder), and HeartView P12/8 Mobile (home monitoring device with cellular modem and voice assistance). The company serves ambulance services, hospitals, telemedicine providers, and home monitoring programs globally. Aerotel's HeartView P12/8 has demonstrated clinical efficacy in published peer-reviewed research showing reduced in-hospital mortality when deployed by ambulance services. The company has successfully completed large-scale national projects, including equipping Hungary's national ambulance service (OMSZ) with ECG monitoring capabilities. Products incorporate voice-guided protocols to enable non-medical personnel to obtain hospital-grade ECG recordings. The company emphasizes one-stop integration support from solution design through implementation and ongoing operations. Founded in 1998, Aerotel maintains global headquarters in Holon, Israel, with international distribution through medical device distributors and service partners.

Transonic Systems Inc. is a medical device manufacturer specializing in ultrasonic Transit-Time blood flow measurement technologies. Founded in 1983 and headquartered in Ithaca, New York, the company provides precision measurement solutions for surgical, clinical, research, and OEM applications. Transonic's product portfolio includes intraoperative blood flow meters for cardiothoracic, cerebrovascular, transplant, and microvascular surgery; hemodialysis flow monitors for vascular access assessment; mechanical circulatory support flow measurement systems for ECMO and cardiopulmonary bypass; tubing flowsensors for biomedical research and device manufacturing; and comprehensive life science research instrumentation for blood flow, pressure, and cardiac output measurement. The company also offers Transonic-Inside™, a customizable OEM integration program enabling medical device developers to embed advanced flow measurement capabilities into their platforms. With global operations across the US, Europe, Asia, Japan, and Taiwan, Transonic serves hospitals, research institutions, and medical device manufacturers seeking gold-standard accuracy and validation-backed measurement solutions.